
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Food and Drug Administration granted approval for the use of Reyataz (atazanavir), Bristol-Myers Squibb's protease inhibitor, on June 20. A study presented at the 16th International Conference on Antiviral Research showed that the investigational drug Ampligen, an immune modulator, may be helpful in delaying HIV viral load rebounds in people taking treatment breaks. Studies are ongoing. GlaxoSmithKline has obtained a licensing agreement from Swedish company Medivir to develop MIV-210, an experimental nucleoside reverse transcriptase inhibitor that in previous tests has successfully treated drug-resistant HIV and drug-resistant hepatitis B. Two studies in the May 29 issue of The New England Journal of Medicine indicated that the use of Fuzeon, Roche and Trimeris's fusion inhibitor, by people resistant to other anti-HIV medications can double the chance to achieve an undetectable viral load. A study in the June issue of the Journal of Clinical Endocrinology and Metabolism reported that testosterone replacement therapy using Testim gel, from Auxilium Pharmaceuticals, can be effective in treating low testosterone levels'as measured through increases in sexual motivation and desire. Testim use has also been linked to improvements in lean muscle mass. Data from an ongoing clinical trial presented at the XII International Drug Resistance Workshop showed that after nearly two years of treatment with a drug cocktail that includes Viread, Gilead Sciences' nucleotide reverse transcriptase inhibitor, less than 3% of previously treatment-naive patients develop resistance to the drug. A 48-week European study of Trizivir, a combination antiretroviral medication from GlaxoSmithKline, indicated that switching to Trizivir after successful multidrug treatment is as effective in suppressing HIV levels as continuing a regimen that includes a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor. Trizivir also was shown to significantly lower cholesterol and triglyceride levels. A Brazilian study showed that Edronax, an antidepression drug, can be safe and effective for HIV-positive people suffering from major depressive disorder. Two studies in the May 1 edition of the Journal of Acquired Immune Deficiency Syndromes showed that switching from Bristol-Myers Squibb's Zerit to GlaxoSmithKline's Ziagen can result in modest improvements to lipoatrophy in the limbs. But because the rate of fat restoration is slow, researchers say visible results should not be expected within the first year of switching medications. A 24-week study reported in the February edition of the Journal of Acquired Immune Deficiency Syndromes indicated that treatment with the corticosteroid prednisone does not decrease the occurrence of rash associated with use of Viramune, Boehringer Ingelheim's nonnucleoside reverse transcriptase inhibitor. Researchers in New York report that a study of Lamictal, GlaxoSmithKline's antiepilepsy drug, demonstrated that the medication may be helpful in treating pain caused by HIV-related peripheral neuropathy. Boehringer Ingelheim has announced the launch of its Patient History Card program, through which HIV-positive inmates will be issued a foldable wallet-size card to help them manage their medical care both inside and outside of correctional facilities. The card has sections to record medications being taken, viral load measurements, CD4-cell counts, drug allergies, vaccinations, and other critical information. The cards can be ordered free of charge by any U.S. correctional facility. Canadian biotechnology firm Theratechnologies has announced the start of a Phase II clinical trial testing the use of ThGRF, a synthetic human growth hormone, to treat HIV-related lipodystrophy. ThGRF has previously been studied as a treatment for type 2 diabetes. GlaxoSmithKline has announced that it is cutting the price of its anti-HIV medications by as much as 47% for 63 developing nations, including all sub-Saharan African countries. The Pfizer Foundation has announced its Southern HIV/AIDS Prevention Initiative, through which the foundation will provide $3 million over three years for community-based HIV prevention groups operating in nine Southern states.
DON'T MISS THE OUT100 SPECIAL 3 DAY MARATHON STARTING NOVEMBER 24TH!
Journey through the year’s influential Out100 – the most iconic and long-standing celebration of LGBTQ+ icons and allies – in a 1-hour television special spotlighting the LGBTQ+ people shaping the world today.
WATCH & LIVESTREAM ON ADVOCATECHANNEL.COM
AND ON THE ADVOCATE CHANNEL APP
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
PEPFAR in Peril: The Far-Right Wants to End the Lifesaving Global HIV Program
October 24 2023 1:52 PM
Plus Nov/Dec Issue: PEPFAR in Danger & Our Allies and Advocates of the Year
October 23 2023 11:53 AM
Trending stories
Most Recent
Recommended Stories for You
HIV Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.